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Background. Liquid-based Pap (L-Pap) media are used for Pap and human papillomavirus (HPV) testing. Objectives.T oc o m p a r e
RealTime High Risk (HR) HPV testing of a new collection kit (Cervi-Collect) and PreservCyt L-Pap specimens. To determine
ease of use and safety of Cervi-Collect. Methods.L - P a ps a m p l e s( n = 203) were tested with HC2 and RealTimeH RH P Va n d
Cervi-Collect with RealTime HR HPV. Discordant samples were genotyped. Results. L-Pap and Cervi-Collect specimens tested by
RealTime HR HPV showed 93.1% agreement (Kappa 0.86). RealTime HR HPV and HC2 on L-Pap had 90.3% agreement (Kappa
0.80).RealTimeHRHPVonCervi-CollectandHC2onL-Papshowed88.2%agreement(Kappa0.76).Sixteenof21sampleswhich
were HC2 negative and RealTime HR HPV positive on L-Pap or Cervi-Collect contained HR HPV genotypes. Eleven healthcare
collectors were in strong agreement on a usability and safety questionnaire. Conclusion. Cervi-Collect samples were easy to collect
and showed strong agreement with L-Pap samples tested with RealTimeH RH P Vo rH C 2 .
1.Introduction
High-risk human papillomaviruses (HR HPV) are a major
cause of cervical cancer [1]. HR HPV testing either adjunc-
tively with cytology or as the primary screening test has
shown increased sensitivity for detecting CIN2+ precan-
cerous lesions when compared with Pap testing alone [2].
ThinPrep PreservCyt Solution and SurePath Preservative
Fluid are transportation and storage media enabling Pap
and HPV testing. PreservCyt liquid-based (L-Pap) medium
has been validated with the Abbott RealTimeH RH P V
assay. In cases where Pap testing is performed using non-
L-Pap samples or HPV testing is performed as the primary
screening method, a cervical specimen is collected for HPV
testing. A collection brush and transportation medium kit
(Cervi-Collect)wasdesignedbyAbbottMolecularfortesting
with the Abbott RealTime HR HPV assay. The principles and
analytical performance of this assay have been described [3],
andthereareseveralreportscomparingittoHC2inarchived
samples[4–6] and to various DNA and RNA detection meth-
ods in L-Pap samples [7–9].
The aims were as follows: (a) to compare the perfor-
mance of the RealTime HR HPV assay by testing Cervi-
Collect and PreservCyt L-Pap specimens, (b) to compare the
RealTime HR HPV and HC2 assays on L-Pap specimens, (c)
totestdiscordantsamplesinalineararray(LA)assay,and(d)
toanalyzethestrengthofagreementofhealthcareworkerson
ease of use and safety of the collection device and its package
insert using a questionnaire.
2.MaterialandMethods
A total of 203 women attending a women’s health clinic
undergoing a routine gynecological exam or a follow-up
examduetoanabnormalPaporpositiveHRHPVtestsigned
consent to have 2 cervical specimens collected: the ﬁrst
was collected with a Cervex-Brush (Rovers Medical devices,
Oss, The Netherlands) and placed into an L-Pap PreservCyt2 Journal of Oncology
collection medium tube (Hologic Inc, Marlborough, Mass,
USA) and the second was collected with the Cervi-Collect
brush and placed into a Cervi-Collect transportation tube.
Specimen collection was performed according to the respec-
tive manufacturers’ instructions. The PreservCyt sample
was processed for cytology in the Pathology Laboratory at
the Juravinski Hospital, Hamilton, ON, Canada, and the
remainder of the sample was sent to the Infection Research
Laboratory (IRL) at the St. Joseph’s Healthcare Hamilton,
Hamilton, ON, Canada. Both samples were received within
24 hours in the IRL.
2.1. HC2 Testing. The L-Pap sample was tested for HR HPV
with the HC2 test (Qiagen, Gaithersburg, Md, USA) at
the IRL according to the package insert. Previous positive
and negative clinical samples were included with each run
as controls. Samples were scored negative if relative light
units/cutoﬀ(RLU/CO)ratioswere<1.0,indeterminatewhen
≥1.0 and <2.5, and positive when ≥2.5. Indeterminate sam-
ples were repeated in duplicates: a sample with an RLU/CO
ratio ≥1.0 in either replicate was considered positive.
2.2. RealTime HR HPV Testing. The Cervi-Collect sample
and one milliliter of the L-Pap sample were packaged and
shipped to Abbott Diagnostics in Wiesbaden, Germany,
where they were tested in a blinded fashion with the
RealTime HR HPV assay on the Abbott m2000 instru-
ment. The automated test procedure consisted of sample
preparation, reaction assembly, real-time PCR, and result
reporting [3]. During sample preparation using the Abbott
m2000sp, 0.4mL of sample was processed using the Abbott
mSample Preparation SystemDNA where it was lysed with
chaotropic reagents, allowing the DNA to be captured on
magnetic microparticles. The bound puriﬁed DNA was
washed and then eluted. An ampliﬁcation master mix was
created with AmpliTaq Gold enzyme (Roche Molecular
Systems Inc., Branchburg, NJ, USA), magnesium chloride,
and an oligonucleotide reagent containing primers, probes,
and dNTPs. The PCR reaction was then assembled in a
96-well optical reaction plate by combining aliquots of the
master mix and the extracted DNA eluate. Thermocycling
and ﬂuorescence detection of the ampliﬁed products were
carried out in the Abbott m2000 real-time PCR instrument,
and results were automatically reported. The assay detects
14 HR HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, and 68) with type speciﬁc detection for types
16 and 18 and detection of the other 12 non-HPV 16/18
t y p e sa sag r o u p .As e p a r a t ed e t e c t i o nc a t e g o ryo fβ-globin is
included as an internal control to validate sample adequacy,
DNA recovery, and PCR eﬃciency. Results for each sample
were reported based on all three HPV signals, corresponding
to HPV16, HPV 18, and non-HPV 16/18 HR types, as well as
the internal control signal.
2.3. LA Testing. Samples which showed discordant results
after testing by HC2 and RealTime HR HPV assays were
tested using the LA HPV Genotyping Test (Roche Molecular
Table 1: Agreement between Cervi-Collect and PreservCyt L-Pap
specimens tested by the Abbott RealTime HR HPV assay.
Abbott RealTimeH RH P V
with Cervi-Collect
+ −




Positive agreement—85.7% (84/98); Negative agreement—88.2% (105/
119); Overall agreement—93.1% (189/203) (kappa = 0.86).
Systems Inc., Branchburg, NJ, USA) following the manu-
facturer’s protocol. PCR was performed in a ﬁnal reaction
volume of 100μL containing 50μL of kit master mix. The
genotyping strips were visually interpreted using the HPV
reference guide provided in the kit package insert. The same
high-risk genotypes represented in the Abbott assay were
considered high risk.
2.4. Questionnaires. Sample collectors (physicians and
nurses) were asked to complete a questionnaire rating
whether the product labeling information was adequate and
easy to understand in the following areas: the intended use
statement, the instructions for safe use, collection, storage,
and transport, and limitation of use statement in the package
insert. They also evaluated the usability aspects (such as
whether the kit package was easy to open, whether the tube
cap was easy to take oﬀ and replace, and whether any leakage
was present) as well as the safety aspects for the collection kit
and instructions. In total, eleven questions were answered by
each of the eleven collectors. Each question was answered on
a scale of 1 to 5, with 5 indicating strong agreement with a
statementand1iftherewasstrongdisagreement.Theoverall
rating across all collectors for each question was calculated
as the combined score as a percentage of a maximal score of
55 (i.e., 11 times 5).
2.5. Statistical Analysis. Agreement between tests was as-
sessed by kappa statistic (κ).
3. Results
There was strong agreement between the L-Pap and Cervi-
Collect specimens tested by RealTimeH RH P V( Table 1).
The positive agreement was 85.7% (84/98), negative agree-
mentwas88.2%(105/119),andoverallagreementwas93.1%
(189/203) (Kappa 0.86). There were 8 L-Pap samples with
insuﬃcient volume for HC2 testing (4 were from patients
who were negative in Cervi-Collect and L-Pap samples and
4w e r ep o s i t i v ei nb o t hb yR e a l T i meH RH P V ) .Table 2
shows agreement between RealTime HR HPV and HC2
performed on 195 L-Pap specimens. The assays agreed on
73 positives and 103 negatives. There were 15 samples
w h i c hw e r ep o s i t i v eb yt h eR e a l T i me HR HPV test and
negative by HC2, and 4 other samples which were positive
by HC2 but negative by the RealTime HR HPV test. The
positive agreement was 79.3% (73/92), negative agreement
was 84.4% (103/122), and the overall agreement was 90.3%Journal of Oncology 3









































Figure 1: Evaluation of the Cervi-Collect package insert, safety, and usability rated by 11 healthcare collectors. (Each of the eleven
questionnaire categories were graded by the collectors, with 5 being the most favorable because of total agreement with the statement. The
ﬁnal rating was based on the combined score from all the collectors as a percentage of the maximal score of 55. E.g., 100% is representative
of 11 healthcare collectors giving a combined score of 55).
Table 2: Correlations between Abbott RealTimeH RH P Va n d
Hybrid Capture 2 with PreservCyt L-Pap Samples.
Abbott RealTimeH RH P V
with PreservCyt L-Pap
+ −




Positive agreement—79.3% (73/92); Negative agreement—84.4% (103/
122); Overall agreement—90.3% (176/195) (kappa = 0.80).
Table 3: Correlation between Abbott RealTimeH RH P Vw i t h
Cervi-Collect and Hybrid Capture 2 with PreservCyt L-Pap Sam-
ples.
Abbott RealTimeH RH P V
with Cervi-Collect
+ −




Positive Agreement—75.3% (70/93); Negative agreement—81.6% (102/
125); Overall agreement—88.2% (172/195) (kappa = 0.76).
(176/195) (Kappa 0.80). When the RealTimeH RH P Vt e s t
was performed on Cervi-Collect specimens and HC2 was
performedonL-P ap(Table 3),positiveagreementwas75.3%
(70/93), negative agreement was 81.6% (102/125), and
overall agreement was 88.2% (172/195) (Kappa 0.76).
Table 4 summarizes the results of LA testing of 28
discordant samples from the 3 testing strategies (HC2 on L-
Pap, RealTime HR HPV on L-Pap, and RealTimeH RH P V
on Cervi-Collect). Samples from 16 of 21 patients with
a negative HC2 result and a positive RealTimeH RP C R
result obtained either from L-Pap or Cervi-Collect samples
contained HR HPV genotypes. Samples from 4 patients
(026, 040, C121, and 190) which were positive by HC2 and
negative by the RealTime HR HPV assay in the L-Pap and
Cervi-Collect samples contained low-risk HPV genotypes.
Three patients (099, C169, and C193), which were HC2 and
RealTime positive in L-Pap but were negative in the Cervi-
Collect sample, contained HR genotypes.
Figure 1 summarizes the outcomes from the question-
naires. Four of 11 categories received a full score (100%)
out of a maximal score of 55 (5 from all 11 collectors), and
the other 7 categories were graded at the maximum by most
collectors (8 or greater) with an overall rating between 93%
and98%.Thelowerscores(93%)wererecordedincategories
for unscrewing and recapping the tube.
4. Discussion
ThenewCervi-CollectkitcomparedwelltoPreservCytwhen
tested by the RealTime HR HPV assay (Table 1), showing
strong agreement of 93.1% (Kappa = 0.86). Analysis of the
98 samples which were positive in either sample type from
Table 1 showed that 27 were positive in the type 16 signal
(with or without the non-HPV 16/18 HR HPV signal),
12 were positive in the type 18 signal, 3 were positive
in both the HPV 16 and 18 signals, and the rest were
positive only in the non-HPV 16/18 HR HPV signal. The
higheragreementbetweenthetwoRealTimeHRHPVresults
for diﬀerent transport media compared to that between
RealTime HR HPV and HC2 was mainly due to more
positives in agreement (n = 84 in Table 1 versus 70 or 73
in Tables 2 and 3,r e s p . ) .
Comparing assays in Tables 2 and 3 showed more cases
of HC2 negative/RealTime HR HPV positive than HC2 posi-
tive/RealTime HR HPV negative samples. These diﬀerences
are consistent with ﬁndings in other studies [7–9]w h i c h
showed that the RealTime HR HPV assay detected the same
number or more cases of HPV infection than the HC2 test.4 Journal of Oncology
Table 4: Comparison of discordant samples tested by linear array (LA).
Patient number RealTimeH RH P Vo n
Cervi-Collect RealTime HR HPV on L-Pap HC2 on L-Pap HPV genotypes1
025 HR HPV HR HPV NEG 59, 66, 68,8 1
029 HR HPV HR HPV NEG 45
058 HR HPV HR HPV NEG 51
084 HR HPV HR HPV NEG 16, 18, 39, 51, 54, 66,
CP6108
085 HR HPV HR HPV NEG 51, 66
C104 HR HPV HR HPV NEG 31,6 2
C129 HR HPV HR HPV NEG 39, 66
C158 HR HPV HR HPV NEG 52
C156 HPV 18 HPV 18 NEG 18,8 4
177 HPV 16 HPV 16 NEG 16
C112 HR HPV Not Detected NEG NEG
C131 HR HPV Not Detected NEG NEG
C173 HR HPV Not Detected NEG 16, 59, 62, 70
C182 HPV 16 Not Detected NEG 16, 40, 53, 55
186 HPV 16 Not Detected NEG 81, CP6108
C167 HPV 18 Not Detected NEG 18, 42, 73
081 Not Detected HR HPV NEG 35, 52, 59
C128 Not Detected HR HPV NEG 18
099 Not Detected HR HPV POS 51, 54, 56,6 2
C169 Not Detected HR HPV POS 56,8 4
060 Not Detected HR HPV NEG NEG
070 Not Detected HPV 16 NEG 16
095 Not Detected HPV 16 NEG NEG
C193 Not Detected HPV 16 POS 16
026 Not Detected Not Detected POS IS39
040 Not Detected Not Detected POS 40, 53, CP6108
C121 Not Detected Not Detected POS 53
190 Not Detected Not Detected POS 81, 84
1High-risk HPV genotypes are bolded.
The HR HPV positive samples that were not detected by the
HC2 test contained HR genotypes by the LA test (Table 4).
There were 16 patients positive by RealTimeH RH P Vi n
the Cervi-Collect sample and negative by HC2 in the L-Pap
sample, 13 of which contained HR HPV by LA testing. Ten of
the 13 were also positive by RealTime HR HPV in the L-Pap
samples. Of the total 28 discordant samples, 24 were positive
for HPV and 19 showed the presence of HR HPV genotypes
by LA testing. Of these 19 samples, 13 Cervi-Collect samples
were identiﬁed as HR HPV positive by the RealTimeH R
HPV assay, 16 L-Pap samples positive by RealTimeH R
HPV, and 3 L-Pap samples positive by HC2 (Table 4). The
study was not designed to follow patients to colposcopy and
biopsy, so one can only speculate what the signiﬁcance of
these additional positive infections would be in predicting
precancerous lesions. Examination of the 7 samples positive
by HC2 and negative by RealTimeH RH P Vo nC e rvi - C o l l e c t
revealed 3 samples that were conﬁrmed positive by LA and
RealTime HR HPV on the L-Pap sample. All 3 samples
contained a low level of HPV targets as indicated by results
from both assays. Because the new collection device was
experimental, the L-Pap sample was required to be collected
ﬁrst and the Cervi-Collect brush was used to collect the
second sample. Low levels of target, collection order, and
analytical sensitivity diﬀerences for HC2, RealTimeH RH P V ,
and LA may contribute to variability of assay comparison.
The other 4 samples, only positive by HC2 testing, were
shown to contain no HR HPV but a variety of low-risk
(LR) genotypes by LA (Table 4, patients 26, 40, C121, and
190). Cross-reactivity of the HC2 test with low-risk HPV
genotypes has been reported previously. Sandri et al. [10]
showed that low risk genotypes such as HPV types 6, 42,
62, 71, 73, and 81 were found to be reactive in the HR HC2
test. Castle et al. [11] showed that genotypes not targeted in
the HR HC2 panel most often testing positive were HPV 82
(80%), HPV 70 (59.1%), and HPV 67 (56.3%).Journal of Oncology 5
Analysis of the questionnaire scores (Figure 1) showed
that4oftheelevencategoriesreceivedthemaximumscoreof
5b ya l lr e s p o n d e n t s( 5 5= 100%). Unscrewing and recapping
the tube received scores of 3 or 4 by 3 of the eleven collectors
suggesting that these maneuvers may be diﬃcult for some
c o l l e c t o r sd u et oac e r t a i nd e g r e eo fd e x t e r i t yr e q u i r e d .
5. Conclusion
Because cervical samples may be collected speciﬁcally for
HPV testing, a system suitable for the collection, trans-
portation, and storage of specimens for the detection of
HR HPV DNA by the Abbott RealTimeH RH P Vw a s
developed and evaluated. Cervi-Collect was designed to
achieve eﬃcient cervical collection, optimal sample stability,
and compatibility with the automated sample preparation
instrument (Abbott m2000sp) as the primary input tube.
ThisstudydemonstratedexcellentperformanceoftheCervi-
Collect samples for the detection of HR HPV when tested
with RealTime HR HPV compared with the PreservCyt
L-Pap samples tested with RealTimeH RH P Vo rH C 2 .
The Cervi-Collect samples were not evaluated as a source
for cytological examination. Healthcare collectors showed
strongagreementwiththeusabilityandsafetydesignfeatures
of Cervi-Collect and its package insert. Further studies need
to be conducted to determine the versatility of this new
collection kit for other anatomical sites such as the vagina
[12],anus[13],andoropharynx[14]aswellasothersexually
transmitted infections [15, 16].
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